Navigation Links
CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenue Increase

Achieves Positive Operating Income Excluding Non-Cash Charges

SAN DIEGO, Oct. 9 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) Impedance Cardiography (ICG) technology, today reported financial results for fiscal third quarter 2008.

Sales Highlights of Third Quarter 2008 Compared with Third Quarter 2007

-- Net ICG sales increased 8% to $6.1 million, up from $5.6 million

-- International sales increased 35% to $690,000, up from $513,000

-- 8,456 ICG monitors and modules sold cumulatively to date, up 12% from

7,532 one year ago

-- ICG device sales totaled 220 units, 110 of which were BioZ Dx systems,

7 BioZ monitors, 87 ICG Modules, and 16 Medis ICG monitors, up from a

total of 197 ICG devices

-- Field headcount totaled 71 field sales associates, including 34 U.S.

territory managers and 21 clinical application specialists, up from 64

field sales associates

Key Financial Results of Third Quarter 2008 Compared with Third Quarter 2007
-- ICG gross profit margin was 75%, up from 72%

-- Loss from operations improved 78% to $254,000, down from $1.2 million

-- Net loss from continuing operations was $432,000, or $0.06 per share,

down from $1.4 million, or $0.19 per share

-- Net operating cash used in continuing operations was $461,000, down 61%

from $1.2 million

Additional Operating Milestone for the Third Quarter 2008

-- Announced BioZ(R) ICG technology integrates with General Electric

Healthcare's electronic medical record (EMR) system

Third Quarter 2008 Operating Results Discussion

The Company reported a net sales increase of 8% to $6.1 million for the third fiscal quarter 2008 and a 15% year-to-date sales increase to $18.0 million, up from $15.7 million for the same period a year ago. Third quarter ICG sales growth was driven by a combination of a 12% increase in third quarter ICG device sales along with a 10% increase in the average unit sales price of our ICG Monitors compared with the third quarter of 2007. This increase in average unit selling price is principally due to a proportionately greater number of higher priced BioZ Dx systems sold during the third quarter of 2008, as compared to the third quarter of 2007 and lower sales return reserve requirements.

Gross margin as a percentage of sales increased from 72% to 75% in the third quarter of 2008, largely due to a 10% average unit sales price improvement, lower inventory reserve requirements, reduced manufacturing overhead costs, and a reduction of sales returns reserve.

Operating expenses were reduced 8% (or $398,000) to $4.8 million, driven primarily by improved efficiencies, reduced personnel expenses, lower accounting fees and bad debt provisions, all part of an ongoing cost containment focus in support of the Company's plan to regain profitability.

The operating loss improved 78% to $254,000, compared to an operating loss of $1.2 million for the same period in 2007. The year-to-date operating loss was $1.6 million, a 61% improvement from $4.0 million in the same nine month period of 2007.

CEO Comments and Outlook

Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "We were very pleased with our performance in the third quarter, particularly the rate of improvement we are making in reducing the operating loss. Excluding non-cash expenses for depreciation, amortization and stock option compensation, we experienced positive income from operations for the first time in 15 quarters and one quarter ahead of plan. Achieving our seventh consecutive quarterly year-over-year revenue growth and 15% growth year-to-date is encouraging and a testament to the continued growth potential for ICG."

Perry continued, "Our goal remains to achieve positive operating cash flow in the fourth quarter of 2008 and positive operating cash flow for our full 2009 fiscal year. We'll continue to make judicious investments that drive increased revenue growth and help establish ICG in the treatment guidelines for heart failure and hypertension in the coming years."

Conference Call Information

Michael K. Perry, Chief Executive Officer, and Steve P. Loomis, Chief Financial Officer, will host a summary of CardioDynamics' third quarter 2008 results in a conference call today, Thursday, October 9, 2008, at 4:30 p.m. (EDT). To access the conference call, dial 800-346-7359 (Code 7784). International participants can call 973-528-0008 (Code 7784). A replay of the call will be available for one month following the call at 800-332-6854 (Code 7784). The international replay number is 973-528-0005 (Code 7784). The Internet webcast can be accessed through the Investor Relations section of the Company's website at or at

About CardioDynamics

CardioDynamics International Corporation (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called impedance cardiography (ICG). The Company develops, manufactures and markets noninvasive ICG products and ICG electrodes. The Company's ICG Systems are being used by physicians around the world to help battle the number one killer of men and women--cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems and Mindray. For additional information, please refer to the Company's Web site at

Forward-Looking (Safe Harbor) Statement

Except for historical and factual information contained herein, this press release contains forward-looking statements, such as revenue growth rates and cash flow projections, operating performance and acceptance of ICG technology, the accuracy of which is necessarily subject to uncertainties and risks, including the Company's ability to meet its short and long-term liquidity and capital needs, primary dependence on the BioZ(R) product line, and various uncertainties characteristic of early stage companies, as well as other risks detailed in the Company's filings with the SEC, including its 2007 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Future events and actual results could differ materially from the forward-looking statements. Readers are urged not to place undue reliance on forward-looking statements. The Company does not undertake to update the disclosures contained in this press release.

CardioDynamics International Corporation

In thousands, except per share data (unaudited)

Selected Consolidated Operational Three Months Nine Months

Results Ended Ended

August 31, August 31,

2008 2007 2008 2007

Net sales $6,066 $5,591 $18,008 $15,699

Cost of sales 1,519 1,554 5,066 4,740

Gross margin 4,547 4,037 12,942 10,959

Research and development 386 420 1,070 1,317

Selling and marketing 3,669 3,977 11,112 11,101

General and administrative 714 772 2,246 2,437

Amortization of intangible assets 32 30 96 115

Loss from operations (254) (1,162) (1,582) (4,011)

Other expense, net (175) (232) (533) (680)

Loss before income taxes and minority

interest (429) (1,394) (2,115) (4,691)

Minority interest in income of

subsidiary - (11) (145) (45)

Income tax benefit (provision) (3) 56 (519) (195)

Loss from continuing operations (432) (1,349) (2,779) (4,931)

Income (loss) from discontinued

operations - 496 127 (10,614)

Net loss $(432) $(853) $(2,652) $(15,545)

Net loss per common share:

Basic and diluted $(0.06) $(0.12) $(0.37) $(2.22)

Weighted-average shares used in per

share calculation:

Basic and diluted 7,213 7,031 7,171 7,004

Selected Consolidated Balance Sheet Data

August 31, November 30,

2008 2007

Cash and cash equivalents $6,328 $8,362

Accounts receivable, net 3,861 4,475

Inventory, net 1,195 1,670

Total current assets 11,942 15,164

Long-term assets 4,451 4,703

Total assets 16,393 19,867

Total current liabilities 7,885 5,620

Long-term liabilities 879 4,318

Total liabilities 8,764 9,938

Minority interest 478 407

Shareholders' equity 7,151 9,522

SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardioDynamics BioZ(R) ICG Technology Integrates with General Electric Healthcares Centricity(R) Electronic Medical Record (EMR) System
2. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
3. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
4. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
5. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
6. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. Corgenix Reports Fiscal 2008 Financial Results
Post Your Comments:
(Date:10/12/2015)...  Rebiotix Inc. today announced that U.S. Food ... Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough ... difficile (C diff) infection, a challenging to ... in the U.S. annually. 1 Rebiotix is ... to revolutionize the treatment of debilitating GI diseases ...
(Date:10/12/2015)... 12, 2015  Patara Pharma, a clinical-stage biotechnology ... diseases and conditions, today announced the closing of ... Concurrent with the close of its sale of ... and Security Agreement with Silicon Valley Bank whereby ... Patara will use the funds from the financing ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl Peck, MD, Chairman ... firm as a Premier Expert consultant. NDA Partners Premier Experts are top ... to the company's clients. Premier Experts collaborate to design and implement critical ...
(Date:10/10/2015)... 10 octobre 2015 Le 8 octobre, l,honorable Doris ... Registre du Congrès sa déclaration de soutien à ... autour du plasma (IPAW), qui se tiendra du ... Plasma Protein Therapeutics Association (PPTA) et ... , Sensibiliser l,opinion publique mondiale autour du ...
Breaking Biology Technology:
(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/29/2015)... , Sept. 29, 2015  iDAvatars is excited to ... introduce its product to market. The official announcement was recently ... Economy event in San Francisco , ... platform powered by IBM Watson. "It is both ... first 100 companies to bring to market the cognitive power ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
Breaking Biology News(10 mins):